We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Ovid Therapeutics Sells Off Epileptic Drug Candidate for $856 Million
Ovid Therapeutics Sells Off Epileptic Drug Candidate for $856 Million
Ovid Therapeutics is selling the global rights to an investigational drug for rare epileptic diseases to Takeda Pharmaceutical in a deal worth potentially $856 million — as Ovid shifts gears and focuses on research of new neurological therapies.